These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

543 related articles for article (PubMed ID: 31446239)

  • 1. Novel N-benzylpyridinium moiety linked to arylisoxazole derivatives as selective butyrylcholinesterase inhibitors: Synthesis, biological evaluation, and docking study.
    Vafadarnejad F; Karimpour-Razkenari E; Sameem B; Saeedi M; Firuzi O; Edraki N; Mahdavi M; Akbarzadeh T
    Bioorg Chem; 2019 Nov; 92():103192. PubMed ID: 31446239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and Synthesis of Selective Acetylcholinesterase Inhibitors: Arylisoxazole-Phenylpiperazine Derivatives.
    Saeedi M; Mohtadi-Haghighi D; Mirfazli SS; Mahdavi M; Hariri R; Lotfian H; Edraki N; Iraji A; Firuzi O; Akbarzadeh T
    Chem Biodivers; 2019 Feb; 16(2):e1800433. PubMed ID: 30460743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and Synthesis of Novel Arylisoxazole-Chromenone Carboxamides: Investigation of Biological Activities Associated with Alzheimer's Disease.
    Saeedi M; Rastegari A; Hariri R; Mirfazli SS; Mahdavi M; Edraki N; Firuzi O; Akbarzadeh T
    Chem Biodivers; 2020 May; 17(5):e1900746. PubMed ID: 32154628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and evaluation of novel cinnamic acid-tryptamine hybrid for inhibition of acetylcholinesterase and butyrylcholinesterase.
    Ghafary S; Ghobadian R; Mahdavi M; Nadri H; Moradi A; Akbarzadeh T; Najafi Z; Sharifzadeh M; Edraki N; Moghadam FH; Amini M
    Daru; 2020 Dec; 28(2):463-477. PubMed ID: 32372339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, biological evaluation, and docking study of novel dual-acting thiazole-pyridiniums inhibiting acetylcholinesterase and β-amyloid aggregation for Alzheimer's disease.
    Ghotbi G; Mahdavi M; Najafi Z; Moghadam FH; Hamzeh-Mivehroud M; Davaran S; Dastmalchi S
    Bioorg Chem; 2020 Oct; 103():104186. PubMed ID: 32890993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of new N-benzylpyridinium-based benzoheterocycles as potential anti-Alzheimer's agents.
    Salehi N; Mirjalili BBF; Nadri H; Abdolahi Z; Forootanfar H; Samzadeh-Kermani A; Küçükkılınç TT; Ayazgok B; Emami S; Haririan I; Sharifzadeh M; Foroumadi A; Khoobi M
    Bioorg Chem; 2019 Mar; 83():559-568. PubMed ID: 30471578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New benzyl pyridinium derivatives bearing 2,4-dioxochroman moiety as potent agents for treatment of Alzheimer's disease: Design, synthesis, biological evaluation, and docking study.
    Mollazadeh M; Mohammadi-Khanaposhtani M; Zonouzi A; Nadri H; Najafi Z; Larijani B; Mahdavi M
    Bioorg Chem; 2019 Jun; 87():506-515. PubMed ID: 30928873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and evaluation of novel arylisoxazoles linked to tacrine moiety: in vitro and in vivo biological activities against Alzheimer's disease.
    Rastegari A; Safavi M; Vafadarnejad F; Najafi Z; Hariri R; Bukhari SNA; Iraji A; Edraki N; Firuzi O; Saeedi M; Mahdavi M; Akbarzadeh T
    Mol Divers; 2022 Feb; 26(1):409-428. PubMed ID: 34273065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, biological evaluation and molecular modeling studies of methyl indole-isoxazole carbohydrazide derivatives as multi-target anti-Alzheimer's agents.
    Iraji A; Nikfar P; Nazari Montazer M; Karimi M; Edraki N; Saeedi M; Mirfazli SS
    Sci Rep; 2024 Sep; 14(1):21115. PubMed ID: 39256495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel N-benzylpiperidine derivatives of 5-arylisoxazole-3-carboxamides as anti-Alzheimer's agents.
    Saeedi M; Felegari P; Iraji A; Hariri R; Rastegari A; Mirfazli SS; Edraki N; Firuzi O; Mahdavi M; Akbarzadeh T
    Arch Pharm (Weinheim); 2021 Mar; 354(3):e2000258. PubMed ID: 33226157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of novel coumarin-pyridinium hybrids: In vitro cholinesterase inhibitory activity.
    Vafadarnejad F; Mahdavi M; Karimpour-Razkenari E; Edraki N; Sameem B; Khanavi M; Saeedi M; Akbarzadeh T
    Bioorg Chem; 2018 Apr; 77():311-319. PubMed ID: 29421707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory activities of major anthraquinones and other constituents from Cassia obtusifolia against β-secretase and cholinesterases.
    Jung HA; Ali MY; Jung HJ; Jeong HO; Chung HY; Choi JS
    J Ethnopharmacol; 2016 Sep; 191():152-160. PubMed ID: 27321278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase.
    Huang L; Luo Z; He F; Lu J; Li X
    Bioorg Med Chem; 2010 Jun; 18(12):4475-84. PubMed ID: 20471843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel cinnamic acid-tryptamine hybrids as potent butyrylcholinesterase inhibitors: Synthesis, biological evaluation, and docking study.
    Ghafary S; Najafi Z; Mohammadi-Khanaposhtani M; Nadri H; Edraki N; Ayashi N; Larijani B; Amini M; Mahdavi M
    Arch Pharm (Weinheim); 2018 Oct; 351(10):e1800115. PubMed ID: 30284339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of some new carboxamide and propanamide derivatives bearing phenylpyridazine as a core ring and the investigation of their inhibitory potential on in-vitro acetylcholinesterase and butyrylcholinesterase.
    Kilic B; Gulcan HO; Aksakal F; Ercetin T; Oruklu N; Umit Bagriacik E; Dogruer DS
    Bioorg Chem; 2018 Sep; 79():235-249. PubMed ID: 29775949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, biological evaluation, and molecular modeling studies of quinoline-ferulic acid hybrids as cholinesterase inhibitors.
    Mo J; Yang H; Chen T; Li Q; Lin H; Feng F; Liu W; Qu W; Guo Q; Chi H; Chen Y; Sun H
    Bioorg Chem; 2019 Dec; 93():103310. PubMed ID: 31586704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics and molecular docking of dihydroxanthyletin-type coumarins from Angelica decursiva that inhibit cholinesterase and BACE1.
    Ali MY; Seong SH; Jung HA; Jannat S; Choi JS
    Arch Pharm Res; 2018 Jul; 41(7):753-764. PubMed ID: 30047040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, Biological Evaluation and Molecular Docking Study of Hydrazone-Containing Pyridinium Salts as Cholinesterase Inhibitors.
    Parlar S; Bayraktar G; Tarikogullari AH; Alptüzün V; Erciyas E
    Chem Pharm Bull (Tokyo); 2016; 64(9):1281-7. PubMed ID: 27581632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, Synthesis, and Molecular Docking of Some Novel Tacrine Based Cyclopentapyranopyridine- and Tetrahydropyranoquinoline-Kojic Acid Derivatives as Anti-Acetylcholinesterase Agents.
    Babaee S; Chehardoli G; Akbarzadeh T; Zolfigol MA; Mahdavi M; Rastegari A; Homayouni Moghadam F; Najafi Z
    Chem Biodivers; 2021 Jun; 18(6):e2000924. PubMed ID: 33861892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BACE1 molecular docking and anti-Alzheimer's disease activities of ginsenosides.
    Choi RJ; Roy A; Jung HJ; Ali MY; Min BS; Park CH; Yokozawa T; Fan TP; Choi JS; Jung HA
    J Ethnopharmacol; 2016 Aug; 190():219-30. PubMed ID: 27275774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.